- Home
- ROIV
as 11-21-2024 2:39pm EST
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
| Founded: | 2014 | Country: | United Kingdom |
| Employees: | N/A | City: | HAMILTON HM11 |
| Market Cap: | 8.4B | IPO Year: | N/A |
| Target Price: | $17.69 | AVG Volume (30 days): | 4.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 5.89 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.61 - $13.06 | Next Earning Date: | 11-12-2024 |
| Revenue: | $129,128,999 | Revenue Growth: | 145.68% |
| Revenue Growth (this year): | 48.37% | Revenue Growth (next year): | 13.76% |
Stock Insider Trading Activity of Roivant Sciences Ltd. (ROIV)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Venker Eric | ROIV | President & COO | Oct 20 '24 | Sell | $11.65 | 100,000 | $1,165,000.00 | 617,470 | |
| QVT Financial LP | ROIV | N/A | Sep 25 '24 | Sell | $11.80 | 926,000 | $10,942,820.00 | 23,055,358 | |
| Gold Daniel Allen | ROIV | Director | Sep 24 '24 | Sell | $11.73 | 4,426,000 | $51,820,727.30 | 2,079,059 | |
| MANCHESTER KEITH S | ROIV | Director | Sep 24 '24 | Sell | $11.70 | 503,000 | $5,866,308.20 | 1,277,178 | |
| Kumar Rakhi | ROIV | Chief Accounting Officer | Sep 20 '24 | Sell | $11.89 | 250,000 | $2,972,500.00 | 209,322 | |
| Gline Matthew | ROIV | CEO | Sep 20 '24 | Sell | $11.79 | 1,983,257 | $23,382,600.03 | 17,870,543 |
Latest Roivant Sciences Ltd. News
ROIV Breaking Stock News: Dive into ROIV Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Roivant Sciences' (NASDAQ:ROIV) Shareholders Should Assess Earnings With Caution
GlobeNewswire
9 days ago
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update
GuruFocus.com
10 days ago
Roivant Sciences Ltd (ROIV) Q2 2025 Earnings Report Preview: What To Expect
GlobeNewswire
23 days ago
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024
GlobeNewswire
24 days ago
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
Argus Research
2 months ago
Daily – Vickers Top Buyers & Sellers for 09/27/2024
GlobeNewswire
2 months ago
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
GlobeNewswire
2 months ago
Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator
Compare ROIV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ROIV Roivant Sciences Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.